abstract: Prior study of the combination of @entity12 and high dose @entity7 with @entity3 ( @entity3 ) priming (GCLAC) in relapsed or refractory @entity8 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity9 , @entity7 , @entity3 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity10 ), and @entity2 of GCLAC. @entity12 was administered at 30 mg m(-2) day(-1) * 5 and @entity7 at 2 g m(-2) day(-1) * 5 after @entity3 priming in 50 newly-diagnosed @entity0 ages 18-64 with @entity8 or advanced @entity6 ( @entity6 ) or @entity4 ( @entity1 ). Responses were assessed in the different cytogenetic risk groups and in @entity0 with @entity5 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity0 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity0 with an @entity5 ( @entity5 ), the CR rate was 65%, compared to 85% for those without an @entity5 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity8 and advanced @entity11 .

title: @entity3 priming, XXXX , and high dose @entity7 (GCLAC) for upfront treatment of @entity8 , advanced @entity6 or @entity4 .

answer: @entity12


abstract: Prior study of the combination of @entity12 and high dose @entity7 with @entity3 ( @entity3 ) priming (GCLAC) in relapsed or refractory @entity8 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity9 , @entity7 , @entity3 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity10 ), and @entity2 of GCLAC. @entity12 was administered at 30 mg m(-2) day(-1) * 5 and @entity7 at 2 g m(-2) day(-1) * 5 after @entity3 priming in 50 newly-diagnosed @entity0 ages 18-64 with @entity8 or advanced @entity6 ( @entity6 ) or @entity4 ( @entity1 ). Responses were assessed in the different cytogenetic risk groups and in @entity0 with @entity5 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity0 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity0 with an @entity5 ( @entity5 ), the CR rate was 65%, compared to 85% for those without an @entity5 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity8 and advanced @entity11 .

title: @entity3 priming, @entity12 , and high dose XXXX (GCLAC) for upfront treatment of @entity8 , advanced @entity6 or @entity4 .

answer: @entity7


abstract: Prior study of the combination of @entity12 and high dose @entity7 with @entity3 ( @entity3 ) priming (GCLAC) in relapsed or refractory @entity8 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity9 , @entity7 , @entity3 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity10 ), and @entity2 of GCLAC. @entity12 was administered at 30 mg m(-2) day(-1) * 5 and @entity7 at 2 g m(-2) day(-1) * 5 after @entity3 priming in 50 newly-diagnosed @entity0 ages 18-64 with @entity8 or advanced @entity6 ( @entity6 ) or @entity4 ( @entity1 ). Responses were assessed in the different cytogenetic risk groups and in @entity0 with @entity5 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity0 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity0 with an @entity5 ( @entity5 ), the CR rate was 65%, compared to 85% for those without an @entity5 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity8 and advanced @entity11 .

title: @entity3 priming, @entity12 , and high dose @entity7 (GCLAC) for upfront treatment of XXXX , advanced @entity6 or @entity4 .

answer: @entity8


abstract: Prior study of the combination of @entity12 and high dose @entity7 with @entity3 ( @entity3 ) priming (GCLAC) in relapsed or refractory @entity8 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity9 , @entity7 , @entity3 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity10 ), and @entity2 of GCLAC. @entity12 was administered at 30 mg m(-2) day(-1) * 5 and @entity7 at 2 g m(-2) day(-1) * 5 after @entity3 priming in 50 newly-diagnosed @entity0 ages 18-64 with @entity8 or advanced @entity6 ( @entity6 ) or @entity4 ( @entity1 ). Responses were assessed in the different cytogenetic risk groups and in @entity0 with @entity5 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity0 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity0 with an @entity5 ( @entity5 ), the CR rate was 65%, compared to 85% for those without an @entity5 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity8 and advanced @entity11 .

title: XXXX priming, @entity12 , and high dose @entity7 (GCLAC) for upfront treatment of @entity8 , advanced @entity6 or @entity4 .

answer: @entity3


abstract: Prior study of the combination of @entity12 and high dose @entity7 with @entity3 ( @entity3 ) priming (GCLAC) in relapsed or refractory @entity8 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity9 , @entity7 , @entity3 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity10 ), and @entity2 of GCLAC. @entity12 was administered at 30 mg m(-2) day(-1) * 5 and @entity7 at 2 g m(-2) day(-1) * 5 after @entity3 priming in 50 newly-diagnosed @entity0 ages 18-64 with @entity8 or advanced @entity6 ( @entity6 ) or @entity4 ( @entity1 ). Responses were assessed in the different cytogenetic risk groups and in @entity0 with @entity5 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity0 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity0 with an @entity5 ( @entity5 ), the CR rate was 65%, compared to 85% for those without an @entity5 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity8 and advanced @entity11 .

title: @entity3 priming, @entity12 , and high dose @entity7 (GCLAC) for upfront treatment of @entity8 , advanced @entity6 or XXXX .

answer: @entity4


abstract: Prior study of the combination of @entity12 and high dose @entity7 with @entity3 ( @entity3 ) priming (GCLAC) in relapsed or refractory @entity8 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity9 , @entity7 , @entity3 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity10 ), and @entity2 of GCLAC. @entity12 was administered at 30 mg m(-2) day(-1) * 5 and @entity7 at 2 g m(-2) day(-1) * 5 after @entity3 priming in 50 newly-diagnosed @entity0 ages 18-64 with @entity8 or advanced @entity6 ( @entity6 ) or @entity4 ( @entity1 ). Responses were assessed in the different cytogenetic risk groups and in @entity0 with @entity5 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity0 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity0 with an @entity5 ( @entity5 ), the CR rate was 65%, compared to 85% for those without an @entity5 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity8 and advanced @entity11 .

title: @entity3 priming, @entity12 , and high dose @entity7 (GCLAC) for upfront treatment of @entity8 , advanced XXXX or @entity4 .

answer: @entity6


abstract: BACKGROUND: MicroRNA-126( @entity4 ) has been shown to be frequently down-regulated in a variety of @entity2 and act as a potential @entity2 suppressor. However, its correlations with the clinicopathological characters of @entity2 remain unclear. METHODS: TaqMan quantitative RT-PCR was used to determine the expression level of @entity4 in tissue samples. The associations of @entity4 expression with clinicopathologic variables were analyzed. Kaplan-Meier survival analysis was performed to analyze the association of @entity4 expression with @entity3 ( @entity3 ) of @entity0 . Univariate and multivariate Cox regression analyses were performed. RESULTS: @entity4 expression level in @entity0 @entity2 tissues was significantly lower than that in adjacent nontumorous tissues (mean        SD: 0.59        0.44 vs. 1.00        0.51, P   <   0.0001). Decreased @entity4 expression in @entity2 was found to be significantly associated with lymphatic invasion (P   =   0.002), distant @entity1 (P   <   0.001), FIGO stage (P   =   0.009), and histological grade (P   =   0.005). Kaplan-Meier analysis showed that @entity0 with lower levels of @entity4 had significantly poorer survival than those with higher expression of this miRNA in @entity0 , with a 5-year @entity3 of 45.7% and 70.9%, respectively (P   =   0.002). Multivariate analysis revealed that @entity4 expression (HR   =   3.97, 95% CI: 2.01-20.22; P   =   0.003) was independently associated with the @entity3 . CONCLUSION: Our data suggests the potential of @entity4 as a prognostic biomarker for @entity2 . VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_220.

title: Decreased expression of microRNA-126 is associated with poor prognosis in @entity0 with XXXX .

answer: @entity2


abstract: BACKGROUND: MicroRNA-126( @entity4 ) has been shown to be frequently down-regulated in a variety of @entity2 and act as a potential @entity2 suppressor. However, its correlations with the clinicopathological characters of @entity2 remain unclear. METHODS: TaqMan quantitative RT-PCR was used to determine the expression level of @entity4 in tissue samples. The associations of @entity4 expression with clinicopathologic variables were analyzed. Kaplan-Meier survival analysis was performed to analyze the association of @entity4 expression with @entity3 ( @entity3 ) of @entity0 . Univariate and multivariate Cox regression analyses were performed. RESULTS: @entity4 expression level in @entity0 @entity2 tissues was significantly lower than that in adjacent nontumorous tissues (mean        SD: 0.59        0.44 vs. 1.00        0.51, P   <   0.0001). Decreased @entity4 expression in @entity2 was found to be significantly associated with lymphatic invasion (P   =   0.002), distant @entity1 (P   <   0.001), FIGO stage (P   =   0.009), and histological grade (P   =   0.005). Kaplan-Meier analysis showed that @entity0 with lower levels of @entity4 had significantly poorer survival than those with higher expression of this miRNA in @entity0 , with a 5-year @entity3 of 45.7% and 70.9%, respectively (P   =   0.002). Multivariate analysis revealed that @entity4 expression (HR   =   3.97, 95% CI: 2.01-20.22; P   =   0.003) was independently associated with the @entity3 . CONCLUSION: Our data suggests the potential of @entity4 as a prognostic biomarker for @entity2 . VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_220.

title: Decreased expression of microRNA-126 is associated with poor prognosis in XXXX with @entity2 .

answer: @entity0


abstract: INTRODUCTION: Our study aimed at defining the role of @entity1 as adjunctive therapy after extracorporeal shock wave lithotripsy (ESWL) in @entity0 with stones in the kidney and ureter. MATERIALS AND METHODS: A placebo-controlled, randomized, double-blind clinical trial prospectively performed between February 2008 and September 2009 on 150 @entity0 with 4-20 mm in diameter renal and ureteral stones referred to our ESWL center. After ESWL, all @entity0 randomly assigned to two groups (placebo and @entity1 ). The drugs administration was started immediately after ESWL and was continued for a maximum of 30 days. RESULTS: From 150 @entity0 , 71 in control group and 70 in case group completed the study. Of 71 @entity0 (60.56%) in control group, 43 @entity0 became stone free; and other @entity0 (39.44%) did not succeed in stone expulsion during 12 weeks after ESWL. In case group of 70 @entity0 (71.4%), 50 @entity0 became stone free. Time of stone passage in most of the @entity0 happened between 20th and 30th day in control group (32.6%) and between 10th and 20th day (50%) in case group after ESWL. There is no statistically significant difference between stone passage in two groups (p = 0.116) and location of stone (p = 0.114), but there is statistically significant difference in time of stone passage from onset of treatment in case and control groups (p = 0.002). CONCLUSION: At last, this study suggested that @entity1 facilitate earlier clearance of fragments after ESWL.

title: Is there a role for XXXX after shock wave lithotripsy in the treatment of renal and ureteral calculi?

answer: @entity1


abstract: BACKGROUND: Topical antifungals comprising @entity5 derivatives have been used for the treatment of @entity4 previously, owing to their anti-inflammatory activities. @entity7 , an antifungal agent belongs to @entity3 group, has also anti-inflammatory effects. Currently, there are only a few unpublished studies, in which @entity7 has been used systemically for @entity4 treatment. AIMS: In this single-blind, 8-week study, we investigated the potential efficacy and safety of @entity7 1% cream for the treatment of mild and moderate @entity4 , and compared the results with those of 0.75% @entity2 gel. @entity0 /METHODS: Forty @entity0 , 30 females and 10 males, with @entity4 were enrolled into the study between 2006 and 2007 years. Twenty of the @entity0 were instructed to apply 1% @entity7 cream, whereas others @entity0 of the study population were instructed to use 0.75% @entity2 gel. A total of 32 @entity0 completed the study. Pre-treatment and post-treatment total severity score (TSS) of the disease were determined by assessing the severity of @entity6 , and the number of papules/pustules of the whole face. The overall response rates, differences of pre-/post-treatment scores of each criterium and the percentages of the decrease in TSS of the study groups were compared statistically. RESULTS: There was no statistically significant difference between the groups in terms of age, sex, and disease duration (P = 0.937, 1.000, and 0.055, respectively). No significant difference was found between the mean post-treatment TSSs of the two groups (P = 0.605). The percentage of clearance assessed by the differences between pre-treatment and post-treatment TSSs was 55% in @entity7 group, although the percentage was 45% in @entity2 group, with no statistically significant difference between the groups (P = 0.496). Local side effects including erythema, @entity1 , and burning were mild and transient in both groups, with similar frequencies (P = 0.101). CONCLUSION: This preliminary study suggests that 1% @entity7 cream is an effective and safe treatment for @entity4 , and can be an option for @entity0 who cannot tolerate other modalities.

title: Efficacy of 1% XXXX cream in comparison with 0.75% @entity2 gel for the treatment of @entity4 .

answer: @entity7


abstract: BACKGROUND: Topical antifungals comprising @entity5 derivatives have been used for the treatment of @entity4 previously, owing to their anti-inflammatory activities. @entity7 , an antifungal agent belongs to @entity3 group, has also anti-inflammatory effects. Currently, there are only a few unpublished studies, in which @entity7 has been used systemically for @entity4 treatment. AIMS: In this single-blind, 8-week study, we investigated the potential efficacy and safety of @entity7 1% cream for the treatment of mild and moderate @entity4 , and compared the results with those of 0.75% @entity2 gel. @entity0 /METHODS: Forty @entity0 , 30 females and 10 males, with @entity4 were enrolled into the study between 2006 and 2007 years. Twenty of the @entity0 were instructed to apply 1% @entity7 cream, whereas others @entity0 of the study population were instructed to use 0.75% @entity2 gel. A total of 32 @entity0 completed the study. Pre-treatment and post-treatment total severity score (TSS) of the disease were determined by assessing the severity of @entity6 , and the number of papules/pustules of the whole face. The overall response rates, differences of pre-/post-treatment scores of each criterium and the percentages of the decrease in TSS of the study groups were compared statistically. RESULTS: There was no statistically significant difference between the groups in terms of age, sex, and disease duration (P = 0.937, 1.000, and 0.055, respectively). No significant difference was found between the mean post-treatment TSSs of the two groups (P = 0.605). The percentage of clearance assessed by the differences between pre-treatment and post-treatment TSSs was 55% in @entity7 group, although the percentage was 45% in @entity2 group, with no statistically significant difference between the groups (P = 0.496). Local side effects including erythema, @entity1 , and burning were mild and transient in both groups, with similar frequencies (P = 0.101). CONCLUSION: This preliminary study suggests that 1% @entity7 cream is an effective and safe treatment for @entity4 , and can be an option for @entity0 who cannot tolerate other modalities.

title: Efficacy of 1% @entity7 cream in comparison with 0.75% @entity2 gel for the treatment of XXXX .

answer: @entity4


abstract: BACKGROUND: Topical antifungals comprising @entity5 derivatives have been used for the treatment of @entity4 previously, owing to their anti-inflammatory activities. @entity7 , an antifungal agent belongs to @entity3 group, has also anti-inflammatory effects. Currently, there are only a few unpublished studies, in which @entity7 has been used systemically for @entity4 treatment. AIMS: In this single-blind, 8-week study, we investigated the potential efficacy and safety of @entity7 1% cream for the treatment of mild and moderate @entity4 , and compared the results with those of 0.75% @entity2 gel. @entity0 /METHODS: Forty @entity0 , 30 females and 10 males, with @entity4 were enrolled into the study between 2006 and 2007 years. Twenty of the @entity0 were instructed to apply 1% @entity7 cream, whereas others @entity0 of the study population were instructed to use 0.75% @entity2 gel. A total of 32 @entity0 completed the study. Pre-treatment and post-treatment total severity score (TSS) of the disease were determined by assessing the severity of @entity6 , and the number of papules/pustules of the whole face. The overall response rates, differences of pre-/post-treatment scores of each criterium and the percentages of the decrease in TSS of the study groups were compared statistically. RESULTS: There was no statistically significant difference between the groups in terms of age, sex, and disease duration (P = 0.937, 1.000, and 0.055, respectively). No significant difference was found between the mean post-treatment TSSs of the two groups (P = 0.605). The percentage of clearance assessed by the differences between pre-treatment and post-treatment TSSs was 55% in @entity7 group, although the percentage was 45% in @entity2 group, with no statistically significant difference between the groups (P = 0.496). Local side effects including erythema, @entity1 , and burning were mild and transient in both groups, with similar frequencies (P = 0.101). CONCLUSION: This preliminary study suggests that 1% @entity7 cream is an effective and safe treatment for @entity4 , and can be an option for @entity0 who cannot tolerate other modalities.

title: Efficacy of 1% @entity7 cream in comparison with 0.75% XXXX gel for the treatment of @entity4 .

answer: @entity2


abstract: The objective of this study was to determine if localized ischaemia of the caput epididymis in the ram causes morphological changes similar to those characteristic of @entity4 in @entity0 . This was tested by performing unilateral occlusion of the superior epididymal artery in 10 rams. At the end of 4 (n = 5) or 28 weeks (n = 4), rams were castrated and the testes and epididymides were weighed. Analysis of histological sections at the light microscope level provided quantitative data on lumen diameter and epithelial cell height of the efferent ducts. Qualitative analysis and specific histochemical stains for identification of lipofuscin pigment provided further information on tissue changes. Electron microscopy was performed on the efferent ducts to assess ultrastructural changes. The results revealed that localized ischaemia of the proximal epididymis caused a dramatic change in tubule calibre of the efferent ducts and initial segment resulting in @entity3 . These changes were more severe following 28 weeks of @entity1 . The epithelial cells of the proximal region showed an increase in the number of lysosomes and they became active in phagocytosis of spermatozoa. @entity6 pigment accumulated within the epithelial cells and also in macrophage-like cells that had invaded the lumina, interstitium and intra-epithelial regions of the ducts. On the basis of these observations we conclude that the tissue changes which occur in the ram epididymis as a result of localized ischaemia show a striking similarity to those seen in @entity0 exhibiting @entity4 . This suggests the possible implication of @entity2 in the aetiology of obstructive @entity5 in @entity0 .

title: Effects of ischaemia on the caput epididymis and its relationship to XXXX : a qualitative study in the ram.

answer: @entity4


abstract: The leading @entity2 vaccine candidate, RTS,S, targets the sporozoite and liver stages of the @entity3 life cycle, yet it provides partial protection against disease associated with the subsequent blood stage of @entity1 . Antibodies against the vaccine target, the circumsporozoite protein, have not shown sufficient correlation with risk of clinical @entity2 to serve as a surrogate for protection. The mechanism by which a vaccine that targets the asymptomatic sporozoite and liver stages protects against disease caused by blood-stage parasites remains unclear. We hypothesized that vaccination with RTS,S protects from blood-stage disease by reducing the number of parasites emerging from the liver, leading to prolonged exposure to subclinical levels of blood-stage parasites that go undetected and untreated, which in turn boosts pre-existing antibody-mediated blood-stage immunity. To test this hypothesis, we compared antibody responses to 824 P. falciparum antigens by protein array in Mozambican @entity0 6 months after receiving a full course of RTS,S (n = 291) versus comparator vaccine (n = 297) in a Phase IIb trial. Moreover, we used a nested case-control design to compare antibody responses of @entity0 who did or did not experience febrile @entity2 . Unexpectedly, we found that the breadth and magnitude of the antibody response to both liver and asexual blood-stage antigens was significantly lower in RTS,S vaccinees, with the exception of only four antigens, including the RTS,S circumsporozoite antigen. Contrary to our initial hypothesis, these findings suggest that RTS,S confers protection against clinical @entity2 by blocking sporozoite invasion of hepatocytes, thereby reducing exposure to the blood-stage parasites that cause disease. We also found that antibody profiles 6 months after vaccination did not distinguish protected and susceptible @entity0 during the subsequent 12-month follow-up period but were strongly associated with exposure. Together, these data provide insight into the mechanism by which RTS,S protects from @entity2 .

title: RTS,S Vaccination Is Associated With Serologic Evidence of Decreased Exposure to XXXX Liver- and Blood-Stage Parasites.

answer: @entity3


abstract: We monitored ST segment continuously for at least 3 h after the beginning of lytic treatment in 103 @entity0 undergoing early coronary thrombolysis for acute @entity2 in order to ascertain whether this technique, which has been shown to be useful to assess recanalization of the @entity3 , is also able to identify the improvement in left ventricular function associated with successful reperfusion. Global left ventricular function (assessed in the 30 degrees right anterior oblique projection with the area/length method) and @entity3 zone wall motion (studied with the centerline method) were evaluated at least 4 weeks after the event. Reperfusion was thought to be achieved when ST segment elevation dropped > 50% relative to the most abnormal peak documented at any time in the study. Eighty @entity0 (78%) met the criterium for successful reperfusion (group 1), and 23 (22%) did not (group 2). Both groups had similar clinical and angiographic characteristics. All indexes of global left ventricular function were significantly better in group 1 than in group 2 @entity0 (end-diastolic volume: 176 +/- 51 vs. 209 +/- 76 ml, end-systolic volume: 66 +/- 40 vs. 97 +/- 55 ml, ejection fraction: 65 +/- 13 vs. 57 +/- 11%, respectively, all P < 0.02). Also the severity (-1.6 +/- 1.3 vs. -2.6 +/- 1.01 S.D./chord, respectively, P < 0.001) and the extension of @entity4 in the @entity3 zone (number of chords with > 2 S.D.: 13 +/- 16 vs. 28 +/- 17, respectively, P < 0.0001) were less in group 1 than in group 2 @entity0 . Furthermore, in reperfused @entity0 , both global left ventricular function and regional wall motion were better in those admitted < 60 min from onset of @entity1 . In conclusion, @entity0 with rapid ( > 50%) decrease of ST segment elevation have smaller @entity3 size and better global left ventricular function than @entity0 without electrocardiographic signs of reperfusion as assessed by continuous ST segment monitoring. This suggests that this non-invasive technique is a powerful tool able to identify @entity0 most benefiting from thrombolytic therapy.

title: Non-invasive assessment of reperfusion of the XXXX during coronary thrombolysis and its relation with left ventricular function.

answer: @entity3


abstract: AIM: To study the dynamic and long-lasting expression of @entity3 receptor after acute @entity1 ( @entity1 ) in @entity0 . METHODS: 36 @entity0 were randomly divided into 6 groups (n = 6): Normal group and @entity1 model groups at 6 hours, 24 hours, 3 days, 7 days and 14 days. @entity1 models were produced with the induction of collagenase type VII-S. Immunohistochemical method was used to detect @entity4 protein and RT-PCR technique was used to detect @entity4 mRNA in brain tissue around the haematoma in different groups. RESULTS: @entity4 protein and mRNA were mild positive in normal group. In model groups, intensity of @entity4 expression started to enhance at 6 hours, and enhanced more at 24 hours. @entity4 expression reached the peak at 3 days and began to descend. At 7 days the descent was obvious and there was further descent at 14 days. At each time point, the @entity4 protein positive cell number and @entity4 mRNA absorbance ratio in @entity1 model groups were significantly higher than those in normal group (P < 0.05 or P < 0.01). In addition, @entity4 proteins were obviously expressed in vivo in brain capillary endothelial cell. CONCLUSION: Functional @entity4 exists in brain capillary endothelial cells. Activation of @entity4 after @entity1 due to the stimulation of @entity3 is not only the initiating agent of @entity2 after @entity1 , but also participates the development of @entity2 .

title: [Dynamic and long-lasting expression of XXXX receptor-1 after @entity1 in @entity0 ].

answer: @entity3


abstract: AIM: To study the dynamic and long-lasting expression of @entity3 receptor after acute @entity1 ( @entity1 ) in @entity0 . METHODS: 36 @entity0 were randomly divided into 6 groups (n = 6): Normal group and @entity1 model groups at 6 hours, 24 hours, 3 days, 7 days and 14 days. @entity1 models were produced with the induction of collagenase type VII-S. Immunohistochemical method was used to detect @entity4 protein and RT-PCR technique was used to detect @entity4 mRNA in brain tissue around the haematoma in different groups. RESULTS: @entity4 protein and mRNA were mild positive in normal group. In model groups, intensity of @entity4 expression started to enhance at 6 hours, and enhanced more at 24 hours. @entity4 expression reached the peak at 3 days and began to descend. At 7 days the descent was obvious and there was further descent at 14 days. At each time point, the @entity4 protein positive cell number and @entity4 mRNA absorbance ratio in @entity1 model groups were significantly higher than those in normal group (P < 0.05 or P < 0.01). In addition, @entity4 proteins were obviously expressed in vivo in brain capillary endothelial cell. CONCLUSION: Functional @entity4 exists in brain capillary endothelial cells. Activation of @entity4 after @entity1 due to the stimulation of @entity3 is not only the initiating agent of @entity2 after @entity1 , but also participates the development of @entity2 .

title: [Dynamic and long-lasting expression of @entity3 receptor-1 after XXXX in @entity0 ].

answer: @entity1


abstract: AIM: To study the dynamic and long-lasting expression of @entity3 receptor after acute @entity1 ( @entity1 ) in @entity0 . METHODS: 36 @entity0 were randomly divided into 6 groups (n = 6): Normal group and @entity1 model groups at 6 hours, 24 hours, 3 days, 7 days and 14 days. @entity1 models were produced with the induction of collagenase type VII-S. Immunohistochemical method was used to detect @entity4 protein and RT-PCR technique was used to detect @entity4 mRNA in brain tissue around the haematoma in different groups. RESULTS: @entity4 protein and mRNA were mild positive in normal group. In model groups, intensity of @entity4 expression started to enhance at 6 hours, and enhanced more at 24 hours. @entity4 expression reached the peak at 3 days and began to descend. At 7 days the descent was obvious and there was further descent at 14 days. At each time point, the @entity4 protein positive cell number and @entity4 mRNA absorbance ratio in @entity1 model groups were significantly higher than those in normal group (P < 0.05 or P < 0.01). In addition, @entity4 proteins were obviously expressed in vivo in brain capillary endothelial cell. CONCLUSION: Functional @entity4 exists in brain capillary endothelial cells. Activation of @entity4 after @entity1 due to the stimulation of @entity3 is not only the initiating agent of @entity2 after @entity1 , but also participates the development of @entity2 .

title: [Dynamic and long-lasting expression of @entity3 receptor-1 after @entity1 in XXXX ].

answer: @entity0


abstract: Long-term follow-up studies after endovascular treatment for @entity2 are still rare and inconclusive. The aim of this study was to assess long-term clinical and angiographic outcome of @entity0 with endovascularly treated @entity3 . The Clinical outcome of all 185 @entity0 with endovascularly treated @entity3 were analyzed and 77 out of 122 surviving @entity0 were examined with MRI and MRA nine to 16 years (mean 11 years) after the initial endovascular treatment. Sixty-three @entity0 were deceased at the time of follow-up. The cause of @entity1 was @entity3 -related in 34 (54%) @entity0 . The annual rebleeding rate from the treated @entity3 was 1.3% in the ruptured group and 0.1% in the unruptured group. In long-term follow-up MRA 18 @entity3 (53%) were graded as complete, 11 @entity3 (32%) had neck remnants and five @entity3 (15%) were @entity6 in the ruptured group. Occlusion grade was lower in the unruptured group with 20 @entity3 (41%) graded as complete, 11 (22%) had neck remnants and 18 (37%) were incomplete. However, only three @entity3 were unstable during the follow-up period and needed retreatment. Endovascular treatment of unruptured @entity3 showed incomplete angiographic outcome in 37% of cases. However, @entity4 rate was as low as 0.1%. Endovascular treatment of @entity5 showed incomplete angiographic outcome in 15% of cases and the annual rebleeding rate was 1.3%.

title: Long-term follow-up study of endovascularly treated XXXX .

answer: @entity2


abstract: OBJECTIVE: @entity4 modulates food reward via central @entity4 receptor ( @entity6 ) expressing neurons. Food reward requires stimulation of midbrain @entity1 neurons and is modulated by central @entity4 action, but the exact central mechanisms remain unclear. Stimulatory and inhibitory @entity4 actions on @entity1 neurons have been reported, e.g. by indirect actions on orexin neurons or via direct innervation of @entity1 neurons in the ventral tegmental area. METHODS: We showed earlier that @entity6 neurons in the @entity3 ( @entity3 ) co-express the inhibitory acting neuropeptide @entity5 (GAL- @entity6 neurons). We studied the involvement of GAL- @entity6 neurons to regulate nutrient reward in @entity0 with selective @entity6 deletion from @entity5 neurons (GAL- @entity6 (KO) @entity0 ). RESULTS: We found that the rewarding value and preference for @entity2 over fat was increased in GAL- @entity6 (KO) @entity0 compared to controls. @entity3 GAL- @entity6 neurons innervate orexin neurons, but not the VTA. Further, expression of @entity5 and its receptor @entity7 are decreased in the @entity3 of GAL- @entity6 (KO) @entity0 , resulting in increased activation of orexin neurons. CONCLUSION: We suggest @entity5 as an important mediator of @entity4 action to modulate nutrient reward by inhibiting orexin neurons.

title: @entity4 modulates nutrient reward via inhibitory XXXX action on orexin neurons.

answer: @entity5


abstract: OBJECTIVE: @entity4 modulates food reward via central @entity4 receptor ( @entity6 ) expressing neurons. Food reward requires stimulation of midbrain @entity1 neurons and is modulated by central @entity4 action, but the exact central mechanisms remain unclear. Stimulatory and inhibitory @entity4 actions on @entity1 neurons have been reported, e.g. by indirect actions on orexin neurons or via direct innervation of @entity1 neurons in the ventral tegmental area. METHODS: We showed earlier that @entity6 neurons in the @entity3 ( @entity3 ) co-express the inhibitory acting neuropeptide @entity5 (GAL- @entity6 neurons). We studied the involvement of GAL- @entity6 neurons to regulate nutrient reward in @entity0 with selective @entity6 deletion from @entity5 neurons (GAL- @entity6 (KO) @entity0 ). RESULTS: We found that the rewarding value and preference for @entity2 over fat was increased in GAL- @entity6 (KO) @entity0 compared to controls. @entity3 GAL- @entity6 neurons innervate orexin neurons, but not the VTA. Further, expression of @entity5 and its receptor @entity7 are decreased in the @entity3 of GAL- @entity6 (KO) @entity0 , resulting in increased activation of orexin neurons. CONCLUSION: We suggest @entity5 as an important mediator of @entity4 action to modulate nutrient reward by inhibiting orexin neurons.

title: XXXX modulates nutrient reward via inhibitory @entity5 action on orexin neurons.

answer: @entity4


abstract: OBJECTIVE: To explore the dynamic magnetic resonance (MR) imaging findings of @entity2 and evaluate its pathological correlation. METHODS: Twelve cases with @entity2 confirmed by surgical pathology underwent MR plain scanning and dynamic enhancement scanning before operation. And the MR data were reviewed and analyzed retrospectively in comparison with surgical and pathological results. RESULTS: Twelve lesions were located in right kidney (n = 9) and left kidney (n = 3) with a mean @entity1 diameter of 7.3 cm (range: 3.2 - 12.6 cm). They were located in renal cortex (n = 1), renal medulla (n = 9) and the middle of cortex and medulla with a relatively normal renal shape. Nine lesions appeared global and 3 elliptic in shape. Well-defined margin was showed in 12 lesions and a thin capsule was observed in all lesions. The @entity1 presented a low to middle homogeneous signal intensity on T1WI and intermediates homogeneous signal intensity on fat saturated FSE-T2WI with a hypointense thin capsule and a hyperintense central scar. A mild-to-middle degree of @entity1 enhancement in cortical phase ( @entity1 SI change 120.3% with a standard deviation of 84.3 and a median of 115.2%) was slightly lower, isointense or slightly higher than renal medulla. And obvious enhancement in portal venous phase( @entity1 SI change 173.7% with a standard deviation of 92.4 and a median of 171.5%) was lower than renal medulla. CONCLUSION: @entity2 typically forms large and well-circumscribed global solid masses in renal medulla. With a relatively normal renal shape and a thin capsule, it shows intermediate homogeneous signal intensity on T1WI and T2WI. And a middle degree enhancement with central stellate scar is found in some @entity0 .

title: [Pathological correlation of dynamic magnetic resonance findings for XXXX ].

answer: @entity2


abstract: BACKGROUND: Adhesion molecules play an important role in the development and progression of @entity2 . The aim of this study was to compare concentrations of soluble forms of adhesion molecules in @entity0 with different clinical presentations of @entity2 ( @entity2 ). METHODS: One hundred and twenty-eight @entity0 with @entity2 were divided into three groups; the first group was @entity3 group (AMI group, n = 45), the second group was unstable @entity5 group (UAP group, n = 48), the third group was stable @entity5 group ( @entity10 group, n = 35). We compared them with @entity0 with normal coronary arteries (control group, n = 31). The serum levels of vascular cell adhesion molecule ( @entity8 ), @entity6 ( @entity6 ), @entity7 and @entity9 were measured in all subjects. RESULTS: The serum level of @entity8 in the AMI group was significantly higher than in the UAP, @entity10 and control groups (P < 0.01). The level in the UAP group was significantly higher than the @entity10 group and control group (P < 0.01) and the level in the @entity10 group was significantly higher than in the control group (P < 0.01). The serum @entity6 level was significantly elevated in the AMI, UAP and @entity10 groups as compared to the control group (P < 0.01). The levels of serum @entity7 and @entity9 in the AMI and UAP groups were significantly higher than in the @entity10 and control groups (P < 0.01). CONCLUSIONS: Increased levels of @entity8 and @entity6 , @entity7 and @entity9 , as markers of @entity1 , showed the importance of inflammatory processes in the development of @entity4 and clinical expression of @entity2 . Soluble @entity6 , @entity8 , @entity7 and @entity9 concentrations are useful indicators of the presence of @entity4 and the severity of @entity2 clinical presentation.

title: Levels of soluble adhesion molecules in @entity0 with various clinical presentations of XXXX .

answer: @entity2


abstract: BACKGROUND: Adhesion molecules play an important role in the development and progression of @entity2 . The aim of this study was to compare concentrations of soluble forms of adhesion molecules in @entity0 with different clinical presentations of @entity2 ( @entity2 ). METHODS: One hundred and twenty-eight @entity0 with @entity2 were divided into three groups; the first group was @entity3 group (AMI group, n = 45), the second group was unstable @entity5 group (UAP group, n = 48), the third group was stable @entity5 group ( @entity10 group, n = 35). We compared them with @entity0 with normal coronary arteries (control group, n = 31). The serum levels of vascular cell adhesion molecule ( @entity8 ), @entity6 ( @entity6 ), @entity7 and @entity9 were measured in all subjects. RESULTS: The serum level of @entity8 in the AMI group was significantly higher than in the UAP, @entity10 and control groups (P < 0.01). The level in the UAP group was significantly higher than the @entity10 group and control group (P < 0.01) and the level in the @entity10 group was significantly higher than in the control group (P < 0.01). The serum @entity6 level was significantly elevated in the AMI, UAP and @entity10 groups as compared to the control group (P < 0.01). The levels of serum @entity7 and @entity9 in the AMI and UAP groups were significantly higher than in the @entity10 and control groups (P < 0.01). CONCLUSIONS: Increased levels of @entity8 and @entity6 , @entity7 and @entity9 , as markers of @entity1 , showed the importance of inflammatory processes in the development of @entity4 and clinical expression of @entity2 . Soluble @entity6 , @entity8 , @entity7 and @entity9 concentrations are useful indicators of the presence of @entity4 and the severity of @entity2 clinical presentation.

title: Levels of soluble adhesion molecules in XXXX with various clinical presentations of @entity2 .

answer: @entity0


abstract: PURPOSE: @entity0 with @entity2 have a limited survival prognosis. We retrospectively analyzed data of @entity2 @entity0 with the aim of defining prognostic factors on which individualized treatment strategies might be built on. @entity0 AND METHODS: Seventy-six @entity0 with primary @entity2 (51 @entity3 multiforme, 20 @entity4 , 4 anaplastic oligo- @entity4 , 1 @entity2 ) were postoperatively irradiated with 5 and 8 Me V photons, 2 Gy per fraction to a median total dose of 60 Gy (range 50 to 70 Gy). RESULTS: The youngest quartile of @entity0 (up to 45 years) had the highest 3-year survival rates (mean +/- SE: 15 +/- 8%) and median survival time (17.9 months, 95% confidence interval: 9.2, 24.2 months) as compared to the oldest quartile (> 61 years) with no 3-year survivor and a median survival time of 9.7 months (7.2, 12.3 months). The middle quartiles (46 to 61 years) showed intermediate results. The difference between the youngest and oldest quartile (p = 0.01) and the middle quartile versus the oldest quartile (p = 0.04) was significant. In univariate analysis, @entity1 size (p = 0.04 for -30 mm vs > 50 mm) was of importance. In multivariate analysis only age of the @entity0 reached statistical significance (p = 0.03). As compared to the youngest quartile of @entity0 , the oldest quartile had a relative risk of 2.1 (95% confidence interval: 0.9, 5.1) of dying from the disease; the age group of 46 to 61 years had a relative risk of 2.0 (0.9, 4.3). CONCLUSIONS: Age of the @entity0 is the most important factor for survival prognosis favouring younger age (< or = 45 years). The possible implications for radiation therapy are discussed.

title: Prognostic factors in high-grade XXXX . A multivariate analysis of 76 cases with postoperative radiotherapy.

answer: @entity2


abstract: BACKGROUND: Evidence supporting treatment intensification in @entity1 ( @entity1 ) is limited and controversial. We explored outcomes of infliximab dose increases and accounted for pre-existing trough levels in @entity0 with active @entity1 . METHODS: This study was a retrospective study of 42 @entity1 @entity0 who received increased infliximab following an insufficient response (DAS28 >3.2). Serum concentrations of infliximab and antibodies to infliximab (ATI) and DAS28 and EULAR clinical response parameters were recorded for 1   year. Analyses were performed in three @entity0 groups that were defined by infliximab serum concentration prior to treatment enhancement: no detectable, low (<1.1    g/mL) or high (>= 1.1    g/mL) drug levels. RESULTS: No circulating infliximab was detected in 20 @entity0 (47.6%), but 13 (31%) and 9 (21.4%) @entity0 exhibited low and high levels, respectively. ATI was only detected in @entity0 with no detectable drug levels because the drug interferes with ELISA. DAS28 disease activity globally showed a modest improvement after dose escalation, but this improvement did not persist after 6 and 12   months. Infliximab serum levels increased significantly in the high group (p   =   0.016), but no increase was achieved in the low and no detectable groups. The three study groups exhibited similar disease activity over time, and no improvement was observed in the non-responder EULAR rates. CONCLUSION: These results suggest that the efficacy of an infliximab dose increase is limited, and the response is independent of the infliximab trough serum concentration that is achieved prior to escalation.

title: Effect of Infliximab Dose Increase in XXXX at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions.

answer: @entity1


abstract: OBJECTIVE: To investigate the reliability and feasibility of @entity3 biopsy (SLNB) of @entity4 using combination of lymphoscintigraphy, the gamma probe and @entity5 staining techniques. METHODS: Twenty-three consecutive @entity0 with @entity4 were entered in the study between August 2007 and August 2009. All cases were without clinical evidence of cervical lymph node involvement. The (99)Tc(m)-dextran of 74 MBq (2mCi) was injected intratumorally under ultrasound guidance about 2 h to 5 h prior to surgery. @entity5 was injected around the @entity2 during surgery. Preoperative lymphoscintigraphy, intra-operative hand-held gamma probe detecting and @entity5 staining techniques were used to detect the @entity3 ( @entity3 ). @entity3 biopsies were sent to prepare frozen sections and the results were compared with specimen of routine selective neck dissection. RESULTS: The SLNs were identified in all cases with the combination techniques. The @entity3 identification rates were 87.0% and 100% with @entity5 staining and lymphoscintigraphy plus probe scanning, respectively. @entity1 in SLNs were revealed by frozen-section histology in 12 @entity0 . In one case, SLNs frozen-section were negative, but @entity1 was detected in routine histology. In other case both @entity3 and routine histology were negative, but @entity1 was detected in non- @entity3 (level VI) neck dissection. The overall accuracy of the @entity3 biopsy was 91.3%, positive predictive value 100% and negative predictive value 81.8%. CONCLUSION: The results seem the @entity3 biopsy technique is a feasible and valuable method for detecting cervical lymph node @entity1 and is helpful to decide performing neck dissection in @entity0 with cN0 @entity4 .

title: [Sentinel lymph node biopsy in XXXX ].

answer: @entity4


abstract: OBJECTIVE: To assess the efficacy and safety of bevacizumab plus @entity11 -based regimen for the first line treatment in metastatic @entity2 (mCRC) @entity0 , and to investigate the correlation between serum @entity1 markers including @entity8 and CA19-9 and response as well as prognosis. METHODS: From May 2007 to July 2008, 67 previously untreated mCRC @entity0 received treatment of IFL (n = 25), IFL plus Bevacizumab (n = 20) or FOLFIRI (n = 22). The treatment continued until disease progression or unacceptable @entity4 . The data were retrospectively analyzed. RESULTS: All @entity0 were evaluable for response, survival and @entity4 analysis. The objective response rate of IFL, IFL plus Bevacizumab or FOLFIRI regimen groups was 16.0% (4/25), 35.0% (7/20) and 18.2% (4/22), respectively (  (2) = 6.026, P = 0.049). The median progression-free survival (PFS) of IFL plus bevacizumab group was 7.5 months, significantly improved as compared with 3.7 months in the IFL group and 4 months in FOLFIRI group (  (2) = 11.97, P = 0.003). Of all 67 cases, the one-year survival rate was 47.0%, two-year survival rate was 27.0%, and the median overall survival (OS) was 13.0 months, with no significant difference among the three treatment groups (  (2) = 3.42, P = 0.18). The serum @entity8 and CA19-9 levels were decreased after treatment, but with no significant difference among the three groups (P > 0.05). The common @entity4 profiles of IFL and FOLFIRI regimens were @entity5 and @entity10 , while the @entity4 related to bevacizumab was consistent with that documented in previous literature, such as @entity3 , @entity7 , @entity9 and delayed wound @entity6 . CONCLUSION: The addition of bevacizumab to @entity11 -based regimen significantly improves the response rate and PFS in first-line treatment for @entity0 with mCRC and its @entity4 is well tolerated.

title: [Evaluation of bevacizumab combined with XXXX -based regimen as the first-line treatment for @entity0 with metastatic @entity2 ].

answer: @entity11


abstract: OBJECTIVE: To assess the efficacy and safety of bevacizumab plus @entity11 -based regimen for the first line treatment in metastatic @entity2 (mCRC) @entity0 , and to investigate the correlation between serum @entity1 markers including @entity8 and CA19-9 and response as well as prognosis. METHODS: From May 2007 to July 2008, 67 previously untreated mCRC @entity0 received treatment of IFL (n = 25), IFL plus Bevacizumab (n = 20) or FOLFIRI (n = 22). The treatment continued until disease progression or unacceptable @entity4 . The data were retrospectively analyzed. RESULTS: All @entity0 were evaluable for response, survival and @entity4 analysis. The objective response rate of IFL, IFL plus Bevacizumab or FOLFIRI regimen groups was 16.0% (4/25), 35.0% (7/20) and 18.2% (4/22), respectively (  (2) = 6.026, P = 0.049). The median progression-free survival (PFS) of IFL plus bevacizumab group was 7.5 months, significantly improved as compared with 3.7 months in the IFL group and 4 months in FOLFIRI group (  (2) = 11.97, P = 0.003). Of all 67 cases, the one-year survival rate was 47.0%, two-year survival rate was 27.0%, and the median overall survival (OS) was 13.0 months, with no significant difference among the three treatment groups (  (2) = 3.42, P = 0.18). The serum @entity8 and CA19-9 levels were decreased after treatment, but with no significant difference among the three groups (P > 0.05). The common @entity4 profiles of IFL and FOLFIRI regimens were @entity5 and @entity10 , while the @entity4 related to bevacizumab was consistent with that documented in previous literature, such as @entity3 , @entity7 , @entity9 and delayed wound @entity6 . CONCLUSION: The addition of bevacizumab to @entity11 -based regimen significantly improves the response rate and PFS in first-line treatment for @entity0 with mCRC and its @entity4 is well tolerated.

title: [Evaluation of bevacizumab combined with @entity11 -based regimen as the first-line treatment for @entity0 with metastatic XXXX ].

answer: @entity2


abstract: OBJECTIVE: To assess the efficacy and safety of bevacizumab plus @entity11 -based regimen for the first line treatment in metastatic @entity2 (mCRC) @entity0 , and to investigate the correlation between serum @entity1 markers including @entity8 and CA19-9 and response as well as prognosis. METHODS: From May 2007 to July 2008, 67 previously untreated mCRC @entity0 received treatment of IFL (n = 25), IFL plus Bevacizumab (n = 20) or FOLFIRI (n = 22). The treatment continued until disease progression or unacceptable @entity4 . The data were retrospectively analyzed. RESULTS: All @entity0 were evaluable for response, survival and @entity4 analysis. The objective response rate of IFL, IFL plus Bevacizumab or FOLFIRI regimen groups was 16.0% (4/25), 35.0% (7/20) and 18.2% (4/22), respectively (  (2) = 6.026, P = 0.049). The median progression-free survival (PFS) of IFL plus bevacizumab group was 7.5 months, significantly improved as compared with 3.7 months in the IFL group and 4 months in FOLFIRI group (  (2) = 11.97, P = 0.003). Of all 67 cases, the one-year survival rate was 47.0%, two-year survival rate was 27.0%, and the median overall survival (OS) was 13.0 months, with no significant difference among the three treatment groups (  (2) = 3.42, P = 0.18). The serum @entity8 and CA19-9 levels were decreased after treatment, but with no significant difference among the three groups (P > 0.05). The common @entity4 profiles of IFL and FOLFIRI regimens were @entity5 and @entity10 , while the @entity4 related to bevacizumab was consistent with that documented in previous literature, such as @entity3 , @entity7 , @entity9 and delayed wound @entity6 . CONCLUSION: The addition of bevacizumab to @entity11 -based regimen significantly improves the response rate and PFS in first-line treatment for @entity0 with mCRC and its @entity4 is well tolerated.

title: [Evaluation of bevacizumab combined with @entity11 -based regimen as the first-line treatment for XXXX with metastatic @entity2 ].

answer: @entity0


abstract: OBJECTIVE: To analyze the clinicopathologic characteristics of @entity7 spontaneous regression. METHODS: Retrospective case series study. The clinic and pathologic data of 52 cases of @entity7 spontaneous regression were analyzed retrospectively. All the cases came from 579 cases of @entity7 (without pre-enucleation chemotherapy) archived in Ophthalmic Pathology Laboratory of Beijing Tongren Eye Centre from Jan. 2007 to Dec. 2013. The analyzed factors included @entity3 activity, @entity3 invasion, and tissue changes of uveal and lens. RESULTS: In this study, the @entity0 ' average age was (14.0    8.7) months. There were 33 (63.5%) male and 19 (36.5%) female @entity0 . The rate of @entity7 spontaneous regression was 9.0% (52/579), of which the rate of complete regression was 1.4% (8/579). The most common symptom was leucocoria coupled with red eye 55.8% (29/52). The typical clinicopathologic characteristics were as follows: (1) all or most of all @entity3 cells @entity4 and only @entity3 cell remains were left; (2)most eyeballs showed atrophiabulbi or phthisis bulbi; (3) severe @entity5 occurred in @entity8 , especially in iris and ciliary body combined with pigment cells disintegrating; (4) @entity6 formed coupled with @entity2 , displacement, or wrapped by fibrous connective tissue; (5) in a small number of cases, there were alive @entity3 cells in the retrolaminar optic nerve or choroid in spite of most @entity3 cells had suffered regression, indicating the @entity0 had histopathologic high risk factors and had the dispositions of @entity3 diffusion and @entity1 . CONCLUSIONS: Some untypical clinical manifestation such as leukocoria coupled with red eye or @entity9 bulbi should be paid close attention. The possibility of @entity7 spontaneous regression should be considered. Meanwhile, some cases of @entity7 spontaneous regression with histopathologic high risk factors should be given post-enucleation systemic adjuvant chemotherapy combined with close observations and follow-ups.

title: [ XXXX spontaneous regression: clinical and histopathologic analysis].

answer: @entity7


abstract: Intrathecal injection of @entity4 produced dual effects on sensory and motor functions in the spinal cord of the @entity0 . At a dose of 5 nmol, @entity4 produced an increase in tail flick latency (TFL) as well as a reversible motor @entity1 as assessed by change in the angle of inclined plane. At a dose of 10 or 20 nmol, dynorphin produced a motor @entity1 lasting for up to 24 hours. The effect of @entity4 on the sensory function of the spinal cord was shown by an increase in the vocalization threshold induced by electrical stimulation of the tail, at dose range of 1.25-10 nmol, with a quick onset (5 min) and relatively short duration (within 60 min). Unlike tail flick reaction which involves spinal motor function, tail stimulation-induced vocalization threshold is a relatively pure index for spinal nociceptive activities. The differential effect of dynorphin on sensory and motor function was supported by the evidence that (1) dynorphin-induced analgesic effect (increase in vocalization threshold) was @entity3 reversible, whereas @entity4 -induced motor @entity1 was naloxone resistant. (2) Nor-BNI, a specific antagonist for kappa opioid receptor, blocked the sensory effect of dynorphin, but had no influence on motor effect of dynorphin. It is thus concluded that dynorphin has both analgesic and paralytic effects in spinal cord. The @entity2 shown by an increase of vocalization threshold is an opioid effect, most probably mediated by kappa opioid receptor; the paralytic effect, however, is a non-opioid effect. The increase of TFL induced by dynorphin involves both sensory ( @entity2 ) and motor ( @entity1 ) effects.

title: Comparative study of the analgesic and paralytic effects induced by intrathecal XXXX in @entity0 .

answer: @entity4


abstract: Intrathecal injection of @entity4 produced dual effects on sensory and motor functions in the spinal cord of the @entity0 . At a dose of 5 nmol, @entity4 produced an increase in tail flick latency (TFL) as well as a reversible motor @entity1 as assessed by change in the angle of inclined plane. At a dose of 10 or 20 nmol, dynorphin produced a motor @entity1 lasting for up to 24 hours. The effect of @entity4 on the sensory function of the spinal cord was shown by an increase in the vocalization threshold induced by electrical stimulation of the tail, at dose range of 1.25-10 nmol, with a quick onset (5 min) and relatively short duration (within 60 min). Unlike tail flick reaction which involves spinal motor function, tail stimulation-induced vocalization threshold is a relatively pure index for spinal nociceptive activities. The differential effect of dynorphin on sensory and motor function was supported by the evidence that (1) dynorphin-induced analgesic effect (increase in vocalization threshold) was @entity3 reversible, whereas @entity4 -induced motor @entity1 was naloxone resistant. (2) Nor-BNI, a specific antagonist for kappa opioid receptor, blocked the sensory effect of dynorphin, but had no influence on motor effect of dynorphin. It is thus concluded that dynorphin has both analgesic and paralytic effects in spinal cord. The @entity2 shown by an increase of vocalization threshold is an opioid effect, most probably mediated by kappa opioid receptor; the paralytic effect, however, is a non-opioid effect. The increase of TFL induced by dynorphin involves both sensory ( @entity2 ) and motor ( @entity1 ) effects.

title: Comparative study of the analgesic and paralytic effects induced by intrathecal @entity4 in XXXX .

answer: @entity0


abstract: UNASSIGNED: @entity3 ( @entity3 ) is the most prevalent form of @entity2 characterized by neuritic plaques containing amyloid-b peptide (Ab) and @entity10 . Evidence has been reported that Ab1-42 plays an essential pathogenic role in decreased spine density, impairment of synaptic plasticity, and @entity6 with disruption of memory-related synapse function, all associated with @entity3 . Experimentally, Ab1-42 oligomers perturb hippocampal long-term potentiation (LTP), an electrophysiological correlate of learning and memory. Ab was also reported to perturb synaptic @entity9 ( @entity5 )-recycling by inhibiting excitatory- @entity7 -transporters. Elevated level of extracellular @entity5 leads to activation of perisynaptic receptors, including @entity11 subunit containing NMDARs. These receptors were shown to induce impaired LTP and enhanced long-term @entity4 and proapoptotic pathways, all central features of @entity3 . In the present study, we investigated the role of @entity5 -recycling on Ab1-42-induced LTP deficit in the @entity8 . We found that Ab-induced @entity0 , which was mimicked by the @entity5 -reuptake inhibitor TBOA, could be rescued by blocking the @entity11 subunit of @entity1 receptors. Furthermore, decreasing the level of extracellular @entity5 using a @entity5 scavenger also restores TBOA or Ab induces @entity0 . Overall, these results suggest that reducing ambient @entity5 in the brain can be protective against Ab-induced synaptic disruption.

title: Amyloid-b1-42 Disrupts Synaptic Plasticity by Altering XXXX Recycling at the Synapse.

answer: @entity9


abstract: The non-steroidal anti-inflammatory drug (NSAID) @entity9 ( @entity9 ) is used as intravenous monotherapy incorporated in 0.9% normal saline solution (100 mg @entity9 ampoule + 200 ml normal saline) in the treatment of renal colic. We present our experience in 65 @entity0 complaining of clinically diagnosed renal colic who were treated by intravenous saline- @entity9 . Prospective investigations revaled urinary calculi in 51 @entity0 , @entity7 (crystalluria) in 5, acute @entity6 in 2, severe @entity8 in 2, negative investigations in 3 and @entity2 in 2 @entity0 . Positive response was observed in 93.8% of @entity0 as far as @entity1 relief is concerned. @entity1 relief started within 5-7 minutes after beginning the infusion. Duration of analgesic effect ranged between 4 and 12 hours. Repeating the injection was done for maintenance of @entity4 . Side effects included @entity5 @entity0 , palpitation in 1 @entity0 , @entity1 in 1, muscular @entity10 in 1 @entity0 . @entity9 , an antiprostaglandin, is a powerful anti-inflammatory and potent analgesic. Intravenous saline- @entity9 is a good emergency treatment for @entity3 .

title: Emergency treatment of renal colic with intravenous XXXX .

answer: @entity9


abstract: A 34-year-old @entity0 who was 20 weeks pregnant developed @entity10 while receiving treatment for @entity6 . Because of her septic condition an abortion was performed. The @entity0 received intravenous @entity4 as a pulse treatment for her @entity10 , which was followed by oral @entity7 and oral @entity9 for 6 weeks. After dose reduction the @entity0 had a severe relapse. The @entity1 dose was increased and @entity9 was replaced by @entity2 . The smaller ulcers healed spontaneously, but skin grafting had to be performed for the large @entity5 . The @entity1 therapy was tapered and discontinued. @entity2 was continued for 10 weeks as monotherapy. Subsequently, the @entity0 was free of symptoms for 7 months. Twelve months after the diagnosis of @entity10 the @entity0 developed @entity8 accompanied by a recurrence of the @entity3 .

title: [ XXXX as a precursor of myeloid leukemia].

answer: @entity10


abstract: To evaluate the significance of alterations in cell adhesion-related genes methylation during lung multistep @entity2 induced by the genotoxic carcinogens @entity5 ( @entity6 ) and @entity3 ( @entity4 ), tissue samples microdissected from @entity6 / @entity4 -induced @entity1 lung @entity2 model were subjected to methylation-specific PCR to evaluate the DNA methylation status of @entity14 , @entity7 , @entity11 and @entity10 . Immunohistochemistry was used to determine protein expression of @entity14 , @entity7 , @entity10 and the DNA methyltransferases (DNMTs) 1, 3a and 3b. @entity11 hypermethylation was not detected in any tissue. @entity14 , @entity7 and @entity10 hypermethylation was correlated with the loss of their protein expression during the progression of pathologic lesions. The prevalence of DNA methylation of at least one gene and the average number of methylated genes increased with the histological progression. @entity9 and @entity12 protein expression increased progressively during the stages of lung @entity2 , whereas @entity13 overexpression was only found in several samples. Furthermore, @entity9 protein expression levels were correlated with @entity14 methylation, and @entity12 protein expression levels were correlated with @entity14 , @entity7 and @entity10 methylation. The average number of methylated genes during @entity2 was significantly correlated with @entity9 and @entity12 protein expression levels. Moreover, mRNA expression of @entity14 significantly increased after treatment with DNMT inhibitor @entity8 in @entity14 -methylated @entity0 cell lines. Our findings suggest that an accumulation of hypermethylation accounts for cell adhesion-related gene silencing is associated with dynamic changes in the progression of @entity6 / @entity4 -induced @entity1 lung @entity2 . We suggest that @entity9 and @entity12 protein overexpression may be responsible for this aberrant DNA methylation.

title: Aberrant methylation accounts for cell adhesion-related gene silencing during XXXX and @entity3 induced multistep @entity1 lung @entity2 associated with overexpression of @entity12 .

answer: @entity5


abstract: To evaluate the significance of alterations in cell adhesion-related genes methylation during lung multistep @entity2 induced by the genotoxic carcinogens @entity5 ( @entity6 ) and @entity3 ( @entity4 ), tissue samples microdissected from @entity6 / @entity4 -induced @entity1 lung @entity2 model were subjected to methylation-specific PCR to evaluate the DNA methylation status of @entity14 , @entity7 , @entity11 and @entity10 . Immunohistochemistry was used to determine protein expression of @entity14 , @entity7 , @entity10 and the DNA methyltransferases (DNMTs) 1, 3a and 3b. @entity11 hypermethylation was not detected in any tissue. @entity14 , @entity7 and @entity10 hypermethylation was correlated with the loss of their protein expression during the progression of pathologic lesions. The prevalence of DNA methylation of at least one gene and the average number of methylated genes increased with the histological progression. @entity9 and @entity12 protein expression increased progressively during the stages of lung @entity2 , whereas @entity13 overexpression was only found in several samples. Furthermore, @entity9 protein expression levels were correlated with @entity14 methylation, and @entity12 protein expression levels were correlated with @entity14 , @entity7 and @entity10 methylation. The average number of methylated genes during @entity2 was significantly correlated with @entity9 and @entity12 protein expression levels. Moreover, mRNA expression of @entity14 significantly increased after treatment with DNMT inhibitor @entity8 in @entity14 -methylated @entity0 cell lines. Our findings suggest that an accumulation of hypermethylation accounts for cell adhesion-related gene silencing is associated with dynamic changes in the progression of @entity6 / @entity4 -induced @entity1 lung @entity2 . We suggest that @entity9 and @entity12 protein overexpression may be responsible for this aberrant DNA methylation.

title: Aberrant methylation accounts for cell adhesion-related gene silencing during @entity5 and @entity3 induced multistep XXXX lung @entity2 associated with overexpression of @entity12 .

answer: @entity1


abstract: To evaluate the significance of alterations in cell adhesion-related genes methylation during lung multistep @entity2 induced by the genotoxic carcinogens @entity5 ( @entity6 ) and @entity3 ( @entity4 ), tissue samples microdissected from @entity6 / @entity4 -induced @entity1 lung @entity2 model were subjected to methylation-specific PCR to evaluate the DNA methylation status of @entity14 , @entity7 , @entity11 and @entity10 . Immunohistochemistry was used to determine protein expression of @entity14 , @entity7 , @entity10 and the DNA methyltransferases (DNMTs) 1, 3a and 3b. @entity11 hypermethylation was not detected in any tissue. @entity14 , @entity7 and @entity10 hypermethylation was correlated with the loss of their protein expression during the progression of pathologic lesions. The prevalence of DNA methylation of at least one gene and the average number of methylated genes increased with the histological progression. @entity9 and @entity12 protein expression increased progressively during the stages of lung @entity2 , whereas @entity13 overexpression was only found in several samples. Furthermore, @entity9 protein expression levels were correlated with @entity14 methylation, and @entity12 protein expression levels were correlated with @entity14 , @entity7 and @entity10 methylation. The average number of methylated genes during @entity2 was significantly correlated with @entity9 and @entity12 protein expression levels. Moreover, mRNA expression of @entity14 significantly increased after treatment with DNMT inhibitor @entity8 in @entity14 -methylated @entity0 cell lines. Our findings suggest that an accumulation of hypermethylation accounts for cell adhesion-related gene silencing is associated with dynamic changes in the progression of @entity6 / @entity4 -induced @entity1 lung @entity2 . We suggest that @entity9 and @entity12 protein overexpression may be responsible for this aberrant DNA methylation.

title: Aberrant methylation accounts for cell adhesion-related gene silencing during @entity5 and @entity3 induced multistep @entity1 lung XXXX associated with overexpression of @entity12 .

answer: @entity2


abstract: To evaluate the significance of alterations in cell adhesion-related genes methylation during lung multistep @entity2 induced by the genotoxic carcinogens @entity5 ( @entity6 ) and @entity3 ( @entity4 ), tissue samples microdissected from @entity6 / @entity4 -induced @entity1 lung @entity2 model were subjected to methylation-specific PCR to evaluate the DNA methylation status of @entity14 , @entity7 , @entity11 and @entity10 . Immunohistochemistry was used to determine protein expression of @entity14 , @entity7 , @entity10 and the DNA methyltransferases (DNMTs) 1, 3a and 3b. @entity11 hypermethylation was not detected in any tissue. @entity14 , @entity7 and @entity10 hypermethylation was correlated with the loss of their protein expression during the progression of pathologic lesions. The prevalence of DNA methylation of at least one gene and the average number of methylated genes increased with the histological progression. @entity9 and @entity12 protein expression increased progressively during the stages of lung @entity2 , whereas @entity13 overexpression was only found in several samples. Furthermore, @entity9 protein expression levels were correlated with @entity14 methylation, and @entity12 protein expression levels were correlated with @entity14 , @entity7 and @entity10 methylation. The average number of methylated genes during @entity2 was significantly correlated with @entity9 and @entity12 protein expression levels. Moreover, mRNA expression of @entity14 significantly increased after treatment with DNMT inhibitor @entity8 in @entity14 -methylated @entity0 cell lines. Our findings suggest that an accumulation of hypermethylation accounts for cell adhesion-related gene silencing is associated with dynamic changes in the progression of @entity6 / @entity4 -induced @entity1 lung @entity2 . We suggest that @entity9 and @entity12 protein overexpression may be responsible for this aberrant DNA methylation.

title: Aberrant methylation accounts for cell adhesion-related gene silencing during @entity5 and @entity3 induced multistep @entity1 lung @entity2 associated with overexpression of XXXX .

answer: @entity12


abstract: To evaluate the significance of alterations in cell adhesion-related genes methylation during lung multistep @entity2 induced by the genotoxic carcinogens @entity5 ( @entity6 ) and @entity3 ( @entity4 ), tissue samples microdissected from @entity6 / @entity4 -induced @entity1 lung @entity2 model were subjected to methylation-specific PCR to evaluate the DNA methylation status of @entity14 , @entity7 , @entity11 and @entity10 . Immunohistochemistry was used to determine protein expression of @entity14 , @entity7 , @entity10 and the DNA methyltransferases (DNMTs) 1, 3a and 3b. @entity11 hypermethylation was not detected in any tissue. @entity14 , @entity7 and @entity10 hypermethylation was correlated with the loss of their protein expression during the progression of pathologic lesions. The prevalence of DNA methylation of at least one gene and the average number of methylated genes increased with the histological progression. @entity9 and @entity12 protein expression increased progressively during the stages of lung @entity2 , whereas @entity13 overexpression was only found in several samples. Furthermore, @entity9 protein expression levels were correlated with @entity14 methylation, and @entity12 protein expression levels were correlated with @entity14 , @entity7 and @entity10 methylation. The average number of methylated genes during @entity2 was significantly correlated with @entity9 and @entity12 protein expression levels. Moreover, mRNA expression of @entity14 significantly increased after treatment with DNMT inhibitor @entity8 in @entity14 -methylated @entity0 cell lines. Our findings suggest that an accumulation of hypermethylation accounts for cell adhesion-related gene silencing is associated with dynamic changes in the progression of @entity6 / @entity4 -induced @entity1 lung @entity2 . We suggest that @entity9 and @entity12 protein overexpression may be responsible for this aberrant DNA methylation.

title: Aberrant methylation accounts for cell adhesion-related gene silencing during @entity5 and XXXX induced multistep @entity1 lung @entity2 associated with overexpression of @entity12 .

answer: @entity3


abstract: Background: Current sedation guidelines recommend avoiding @entity4 but express no preference for @entity5 versus @entity6 . In addition, there are limited data on how well randomized controlled trials on sedatives generalize to routine practice where conditions tend to be more varied and complex. Methods: We gathered daily sedative exposure data from all @entity0 on mechanical ventilation for >= 3 days over a 7-year period in a large academic medical center. We compared hazard ratios for ventilator-associated events (VAEs), extubation, hospital discharge, and @entity1 amongst @entity4 , @entity5 , and @entity6 using proportional subdistribution hazard models with competing risks. We adjusted all analyses for ICU type, demographics, comorbidities, procedures, severity of @entity2 , @entity3 , oxygenation, renal function, opioids, neuroleptics, neuromuscular blockers, awakening and breathing trials, and calendar year. Results: We evaluated 9,603 consecutive episodes of mechanical ventilation. @entity4 and @entity5 were associated with increased VAE risk whereas @entity6 was not. @entity5 was associated with less time to extubation compared to @entity4 (HR for extubation 1.4, 95% CI 1.3-1.5). @entity6 was associated with less time to extubation compared to both @entity4 (HR 2.3, 95% CI 2.0-2.7) and @entity5 (HR 1.7, 95% CI 1.4-2.0) but there were relatively few @entity6 exposures available for analysis. There were no differences between any two agents in hazards for hospital discharge or mortality. Conclusions: In this large, real-world cohort, @entity5 and @entity6 were associated with less time to extubation compared to @entity4 but @entity6 was also associated with less time to extubation compared to @entity5 . These possible differences merit further study.

title: Associations between different sedatives and ventilator-associated events, length-of-stay, and mortality in mechanically ventilated XXXX .

answer: @entity0


abstract: PURPOSE: To determine if postoperative external pelvic radiation (EBRT), without vaginal brachytherapy, is sufficient to prevent vaginal cuff and pelvic recurrences in @entity0 with surgical Stage I @entity4 ( @entity3 ). METHODS AND MATERIALS: The records of 122 @entity0 with surgical @entity4 were reviewed. There were 87 @entity0 with @entity3 who received EBRT alone and are the subject of this study. Their radiation records were reviewed. All @entity0 underwent exploration, total abdominal hysterectomy, and bilateral salpingo-oophorectomy (TAH BSO), and pelvic and paraaortic lymph node sampling. They were staged according to the FIGO 1988 surgical staging system recommendations. Postoperatively, pelvic EBRT was administered by megavoltage equipment using four fields, to a total dose of 45 to 50.4 Gy. Actuarial survival and disease free survival were calculated according to Kaplan-Meier Method. RESULTS: Twenty-seven @entity0 with Stage IA Grade 1 or 2 @entity3 with less than one-third myometrial invasion, who did not receive EBRT, and eight @entity0 with histology other than @entity3 (i.e., serous papillary, mucinous, etc.) were not included in the study. For the remaining 87 @entity0 who are in the study group, the median follow-up was 52 months (range: 12-82 months). The 5-year overall survival for these 87 @entity0 was 92%, with a disease-free survival of 83%. There were no @entity1 recurrences in the upper vagina or in the pelvis. Two @entity0 developed @entity5 (no surgery required), and one @entity0 developed @entity2 . CONCLUSION: Adjuvant external pelvic radiation, without vaginal brachytherapy, prevents pelvic and vaginal cuff recurrences in surgical Stage I endometrial @entity3 .

title: Pelvic control following external beam radiation for surgical stage I XXXX .

answer: @entity4


abstract: @entity2 is a disease of the lung epithelial barrier, most often associated with @entity3 in @entity0 . @entity2 and @entity3 are two distinct diseases, but the phenotypic expression of @entity2 depends on atopic status. A better definition of phenotypes of @entity2 would result in better targeting of prevention and treatment modalities. Secondary prevention aims to prevent the onset of @entity2 and the acquisition of new sensitizations in sensitized @entity0 . Studies concerning allergen avoidance are insufficient to reach a definitive conclusion and antihistamines have not been shown to be effective. The results for specific immunotherapy suggest a benefit to prevent transition from @entity5 to @entity2 and the onset of new sensitizations. Tertiary prevention aims to reduce symptoms in @entity0 with an existing @entity1 diagnosis. The avoidance of known @entity4 will only be effective in combination with management of the whole environment. Specific immunotherapy has a real place, in combination with background therapy. It should be used according to guidelines in appropriately treated @entity0 .

title: [Secondary and tertiary prevention of XXXX in @entity0 ].

answer: @entity1


abstract: @entity2 is a disease of the lung epithelial barrier, most often associated with @entity3 in @entity0 . @entity2 and @entity3 are two distinct diseases, but the phenotypic expression of @entity2 depends on atopic status. A better definition of phenotypes of @entity2 would result in better targeting of prevention and treatment modalities. Secondary prevention aims to prevent the onset of @entity2 and the acquisition of new sensitizations in sensitized @entity0 . Studies concerning allergen avoidance are insufficient to reach a definitive conclusion and antihistamines have not been shown to be effective. The results for specific immunotherapy suggest a benefit to prevent transition from @entity5 to @entity2 and the onset of new sensitizations. Tertiary prevention aims to reduce symptoms in @entity0 with an existing @entity1 diagnosis. The avoidance of known @entity4 will only be effective in combination with management of the whole environment. Specific immunotherapy has a real place, in combination with background therapy. It should be used according to guidelines in appropriately treated @entity0 .

title: [Secondary and tertiary prevention of @entity1 in XXXX ].

answer: @entity0


abstract: The term smooth uterine muscle of uncertain malignant potential (STUMPs) indicates a group of uterine smooth @entity6 (SMTs) that cannot be diagnosed unequivocally as benign or malignant. Diagnosis, surgical management, and follow-up of this @entity1 remain controversial, especially in pre-menopausal @entity0 with fertility desire, due to the @entity2 and prolonged survival rate when compared to @entity5 . However, recurrence is estimated between 8.7% and 11% and may include delayed-recurrences. We reported five cases of uterine masses treated by surgical procedure diagnosed as STUMP on final pathology. Four @entity0 underwent a total abdominal hysterectomy with or without salpingo-oophorectomy. One @entity0 underwent excision of uterine mass and subsequent total abdominal hysterectomy plus bilateral salpingo-oophorectomy after the diagnosis of STUMP. All @entity0 in our study remained recurrence-free to date (with a follow up period ranging from 6 to 81 months). Based on our experience and in consideration of the lack of consensus regarding the malignant potential, diagnostic criteria, gold-standard treatment and follow-up, we believe that close multidisciplinary management is mandatory in the event of STUMP. We suggest that gynaecologist, dedicated pathologist (with high level of expertize in gynaecological pathology) and oncologist should work as a team in the counselling and management of this @entity1 from detection till completion of follow up. Furthermore, we recommend immunohistochemistry to investigate the overexpression of @entity4 and @entity3 in order to identify the cohort of @entity0 at increased risk of recurrence who may benefit from more aggressive surgical-oncological strategies.

title: Uterine smooth XXXX of uncertain malignant potential (STUMP): pathology, follow-up and recurrence.

answer: @entity6


abstract: Nowadays, advanced @entity4 is still an incurable disease. Recent researches have led to considerable progress in the treatment of @entity4 . This article reviews the main studies on chemotherapy on @entity4 and discusses the new therapeutic strategies available to date. @entity2 ( @entity2 ) is necessary in chemotherapy for @entity1 . The proportion of population with responders or @entity2 basically maintained similar regardless of regimens. The overall survival after chemotherapy for @entity0 with @entity2 was lower than @entity0 with responders, and higher than @entity0 with progressive disease. Greater benefits could be achieved in @entity0 with effective induction chemotherapy using chemotherapeutic agents for maintenance therapy, whereas the benefits were relatively small for @entity0 with @entity2 . It has been found that @entity3 ( @entity3 ) mutation status had certain correlation with the efficacy of chemotherapy. First-line chemotherapy has shown advantages in effective rate and progression free survival on @entity3 mutant. @entity3 mutation produced significant effects on the efficacy of postoperative adjuvant chemotherapy. @entity0 with @entity3 mutation had a higher effective rate than wild-type @entity3 @entity0 , and @entity0 with responders had a greater benefit in progression free survival from maintenance therapy. However, it is still necessary to carry out more careful and deeper studies and analyses on traditional cytotoxic chemotherapy, to further optimize cytotoxic chemotherapy and to use molecular targeted agents with different mechanisms.

title: Selection of chemotherapy for XXXX is facilitated by new therapeutic strategies.

answer: @entity4


abstract: @entity3 ( @entity3 ) is associated with a variety of diseases, but in recent years it has most frequently been observed with @entity6 . The management of @entity1 lesions and optimal surgical treatment strategies remain controversial. In this study, we explore the clinical diagnosis and treatment of @entity3 by retrospectively analyzing the records of @entity3 @entity0 treated between August 2008 and February 2014. Three female @entity0 and one male @entity0 with an average age of 61 years were diagnosed with @entity3 caused by @entity1 during this period. The predominant symptoms were @entity4 , @entity7 , @entity5 , and @entity8 . Gastrointestinal contrast series combined with fiber endoscopy was the most accurate method of diagnosing the @entity3 , while CT and MRI were helpful in identifying the extent of @entity1 invasion and evaluating the possibility of en-bloc resection. Pathological and immunohistochemical tests, including staining for @entity10 , CK-7, and @entity11 , suggested that three cases originated in the colon and one case in the stomach. All four cases underwent single-stage en-bloc fistula resection; two severely malnourished @entity0 received concurrent colostomies. One @entity0 died of postoperative @entity9 and @entity2 , but the remaining three @entity0 were discharged in improved condition. En-bloc resection followed by adjuvant chemotherapy can result in long term survival. Gastrointestinal contrast series combined with fiber endoscopy showed high sensitivity in the diagnosis of @entity3 . Immunohistochemical staining can be conducted for @entity1 with an unclear source. Single-stage radical en-bloc fistula resection is the recommended surgical treatment, and concurrent colostomy should be considered in severely malnourished @entity0 .

title: Current diagnosis and management of XXXX : a single surgical unit's experience.

answer: @entity1


abstract: OBJECTIVE: The aim of study was to examine the relationship between the dietary nutrition and the prevalence and risk of @entity1 in @entity0 with @entity3 . METHODS: 260 @entity0 with @entity3 and @entity7 meeting criterion were recruited in this cross-sectional study. @entity3 was defined according to NCEP-ATPIII guidelines. Food-frequency questionnaire was performed to collect the information on dietary nutrition. Anthropometric measurements, including body weight, height and waist circumference were collected. Blood pressure, @entity4 , @entity2 , high density lipoprotein- @entity2 and fasting plasma @entity5 , renal function and 24-hour urine protein were measured. The correlations between GFR and actual nutrient intakes of @entity0 were examined. RESULTS: The actual intakes of energy, @entity9 , protein, fat and @entity2 in participate were all significantly higher than recommended nutrient intakes/adequate intakes of Chinese Dietary Reference Intakes. GFR was significantly inversely correlated with energy, protein intake, @entity2 intake, @entity9 intake, @entity8 intake, @entity6 intake and actual protein/energy ratio. Logistic regression analyses showed that actual protein intakes/recommended protein intakes (APIs/RPIs) were significant independent predictors of GFR < 60 ml/min   1.73 m(2). CONCLUSIONS: Dietary nutrition is closely correlated with @entity1 in @entity0 with @entity3 . High protein intakes may be one of the risk factors of @entity1 .

title: Association between the dietary factors and @entity3 with XXXX in Chinese adults.

answer: @entity7


abstract: OBJECTIVE: The aim of study was to examine the relationship between the dietary nutrition and the prevalence and risk of @entity1 in @entity0 with @entity3 . METHODS: 260 @entity0 with @entity3 and @entity7 meeting criterion were recruited in this cross-sectional study. @entity3 was defined according to NCEP-ATPIII guidelines. Food-frequency questionnaire was performed to collect the information on dietary nutrition. Anthropometric measurements, including body weight, height and waist circumference were collected. Blood pressure, @entity4 , @entity2 , high density lipoprotein- @entity2 and fasting plasma @entity5 , renal function and 24-hour urine protein were measured. The correlations between GFR and actual nutrient intakes of @entity0 were examined. RESULTS: The actual intakes of energy, @entity9 , protein, fat and @entity2 in participate were all significantly higher than recommended nutrient intakes/adequate intakes of Chinese Dietary Reference Intakes. GFR was significantly inversely correlated with energy, protein intake, @entity2 intake, @entity9 intake, @entity8 intake, @entity6 intake and actual protein/energy ratio. Logistic regression analyses showed that actual protein intakes/recommended protein intakes (APIs/RPIs) were significant independent predictors of GFR < 60 ml/min   1.73 m(2). CONCLUSIONS: Dietary nutrition is closely correlated with @entity1 in @entity0 with @entity3 . High protein intakes may be one of the risk factors of @entity1 .

title: Association between the dietary factors and XXXX with @entity7 in Chinese adults.

answer: @entity3


abstract: OBJECTIVE: Stent placement for @entity7 has become an alternative treatment technique; however, stent placement for @entity6 remains a technical and clinical challenge. Our purpose was to assess the safety and feasibility of Wingspan stent for @entity0 with symptomatic M1 @entity5 , and its initial effect on prevention of @entity1 events. METHODS: Fifty-three cases with recurrent @entity6 resistant to medical therapy treated by self-expanding stent were reviewed retrospectively (average 58  18.5 years old, 19 @entity0 ). All @entity0 underwent angioplasty and stenting with the Gateway @entity4 , and advised follow-up with DSA or @entity8 at 6th month. RESULTS: @entity0 had an average @entity5 ratio of 76.5  15.4% prior to the treatment. Of the 53 @entity0 , the technical success rate was 98.1% as a whole (52/53). The mean degree of @entity5 reduced from (76.5  15.4)% to (18.2  11.3)%. Complications associated with the procedure include @entity3 (1.89%) and occlusion (3.78%) occurred. During a follow-up of 6 months, there was no recurrence of transient @entity1 attack or @entity2 in 52 cases with successful stenting. Cerebral hemodynamics of MCA using transcranial Doppler monitoring were at normal level (<120 cm/s) in 41 follow-up @entity0 . The follow up angiography at 6 month post-procedure was conducted in 32 @entity0 and showed good patency in stented vessels. CONCLUSIONS: Wingspan stent for symptomatic @entity5 of middle cerebral artery is a safe and feasible procedure. It improves clinical outcome in the intermediate follow up, but its long-term effect remains to be further evaluated.

title: Wingspan stent for symptomatic M1 XXXX of middle cerebral artery.

answer: @entity5


abstract: OBJECTIVE: Disparities in limb salvage procedures may be driven by @entity2 ( @entity2 ) and access to high-volume hospitals. We sought to identify @entity2 factors associated with major amputation in the setting of @entity1 ( @entity1 ). METHODS: The 2003-2007 Nationwide Inpatient Sample was queried for discharges containing lower extremity revascularization (LER) or major amputation and chronic @entity1 (N = 958,120). The Elixhauser method was used to adjust for comorbidities. Significant predictors in bivariate logistic regression were entered into a multivariate logistic regression for the dependent variable of amputation vs LER. RESULTS: Overall, 24.2% of @entity1 @entity0 underwent amputation. Significant differences were seen between both groups in bivariate and multivariate analysis of @entity2 factors, including race, income, and insurance status. @entity3 @entity0 were more likely to be treated at low-LER-volume institutions (odds ratio [OR], 1.74; P < .001). @entity0 at higher-LER-volume centers (OR, 15.16; P <.001) admitted electively (OR, 2.19; P < .001) and evaluated with diagnostic imaging (OR, 10.63; P < .001) were more likely to receive LER. CONCLUSIONS: After controlling for comorbidities, minority @entity0 , those with lower @entity2 , and @entity0 with Medicaid were more likely receive amputation for @entity1 in low-volume hospitals. Addressing @entity2 and hospital factors may reduce amputation rates for @entity1 .

title: Socioeconomic and hospital-related predictors of amputation for XXXX .

answer: @entity1


abstract: Two experiments were conducted to evaluate the effects of dietary fat supplementation and a synthetic progestogen on metabolic hormone patterns and(or) in vitro and in vivo characteristics of induced corpora lutea (CL) in undernourished, post-partum beef @entity0 . Metabolizable energy intake was restricted in all @entity0 in both experiments before calving to achieve a body condition (BC) score of 4 (thin), with @entity0 fed to maintain BW and condition after calving. In Exp. 1, 16 @entity0 were fed isocaloric and isonitrogenous diets after calving with either no added fat (NL, n = 8) or added fat ( @entity2 , n = 8; .374 kg of fat/500 kg BW). In Exp. 2, 32 pluriparous @entity0 that had reached targeted body condition were divided randomly at calving into a 2 x 2 factorial treatment arrangement: 1) @entity2 -no implant; @entity2 -CON, 2) @entity2 -norgestomet implant d 14 to 21; @entity2 -NORG, 3) NL-CON and, 4) NL-NORG. Forty-eight-hour @entity0 removal on d 21 and @entity1 on d 23 were used to induce CL. The @entity2 diet increased (P < .03) serum growth hormone (GH) concentrations, changed the puerperal pattern of serum insulin from cubic (P < .05) to linear (P < .05), and increased (P < .01) the in vitro production of @entity3 by luteal tissue (Exp. 1). In Exp. 2, both @entity2 diets and NORG treatments ( @entity2 -NORG, @entity2 -CON, NL NORG) tended to promote an increased (P < .09) frequency of luteal activity after @entity1 , but only @entity2 -CON and NL-NORG enhanced (P < .04) luteal lifespan.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Metabolic and luteal sequelae to heightened dietary fat intake in undernourished, anestrous beef XXXX induced to ovulate.

answer: @entity0


abstract: The transcriptome is the mRNA pool found within a cell. Transcriptomic discovery approaches include microarray-based technologies as well as sequencing-based technologies. Transcriptomic experiments provide dynamic information about gene expression at the tissue level. The proteome is the pool of proteins expressed at a given time and circumstance. The word PROTEOMICS summarizes several technologies for visualization, quantitation, and identification of these proteins. Protein separation can be accomplished by two-dimensional electrophoresis, use of protein chips with an affinity matrix, or by a variety of advanced chromatographic methods. Mass spectrometry is used to identify the proteins in conjunction with protein sequence databases. Recent proteomic experiments in resting and activated platelets have identified novel signaling pathways and secreted proteins. Platelet transcriptomic studies in essential @entity2 , @entity1 , @entity4 , and an inherited @entity3 are reviewed. Transcript profiling has the potential to distinguish molecular signatures in normal and diseased platelets and to classify prothrombotic @entity0 phenotypes to tailor their therapy.

title: Genomic and proteomic applications in diagnosis of XXXX and classification.

answer: @entity3


abstract: BACKGROUND: Absence of a pathognomonic clinical picture and variable histologic findings often delay diagnosis of nontuberculous mycobacteria (NTM)-induced @entity1 , and antimicrobial therapy varies. OBJECTIVE: We sought to investigate the clinical, microbiologic, and pathological findings of cutaneous NTM infections and response to different treatments. METHODS: Records of @entity0 with NTM infections of the skin confirmed by positive cultures or histologic findings were reviewed. Clinical, microbiologic, and epidemiologic data were collected and skin biopsy specimens were reassessed. RESULTS: The series included 25 cases, one diagnosed by histology and 24 by positive culture: 16 cases with @entity5 , 3 of atypical @entity5 without species identification, and one each with M chelonae, M xenopi, @entity4 , M gordonae, and M fortuitum. One of 16 @entity0 with @entity5 developed @entity2 . Mean interval between clinical presentation and diagnosis was 7.1 months (range: 1-27.3 months). All isolates analyzed for antimicrobial susceptibility pattern were sensitive to @entity3 . LIMITATIONS: Limitations include methods of case collection, retrospective study, and relatively small number of @entity0 . CONCLUSIONS: Diagnosis of NTM should be confirmed by histology and bacteriology studies of tissue cultures. Strong clinical suggestion of @entity5 infection warrants initial empirical treatment to prevent progression to @entity1 . The recommended treatment as indicated by the results of the in vitro susceptibility and clinical response is @entity3 .

title: XXXX of the skin: A retrospective study of 25 cases.

answer: @entity1


abstract: @entity4 ( @entity4 ) exhibits beneficial effects on beta cell mass by both enhancing proliferation and inhibiting apoptosis. The precise mechanism of the anti-apoptotic effect of @entity4 and @entity4 mimetics like exendin-4 has remained elusive. Here, we studied cytokine-induced apoptosis in the pancreatic beta cell line @entity3 and performed a comparative mitochondrial protein pattern analysis using two-dimensional difference gel electrophoresis (2D-DIGE). Cytokine incubation of @entity3 cells increased @entity1 activity about 3-fold, which was reduced by 60% in the presence of exendin-4. Production of reactive @entity0 species in response to cytokines was completely prevented after preincubation with exendin-4. Highly purified mitochondria were obtained and mitochondrial proteins were labeled with Cy-dyes and separated on overlapping zoom 2D gels spanning a pH-range of 4-9. Protein spots with significant changes after cytokine and exendin-4 treatment were identified by MALDI mass spectrometry. Comparing all treatment conditions, comparative mitochondrial proteome analysis allowed to identify 33 different proteins, which were significantly altered between comparison groups. Changes in protein patterns revealed involvement of cytokine-induced electron transport chain damage. Thus, cytochrome bc1 complex subunit I and @entity2 synthase subunit beta were downregulated by 30-40%. This was abrogated by the presence of exendin-4. In conclusion, this study provides further insights into the role of mitochondria in cytokine-induced apoptosis. We show here that exendin-4 significantly counter-regulates the reduced abundance of electron transport chain proteins, leading to a reduction of oxidative stress and most likely contributing to the anti-apoptotic action of this drug.

title: Anti-apoptotic action of exendin-4 in XXXX beta cells: comparative protein pattern analysis of isolated mitochondria.

answer: @entity3